Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc.

Court of Chancery of Delaware·Decided December 18, 2020·No. C.A. No. 2020-0593-PAF·Published

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE )

ALEXANDRIA VENTURE ) INVESTMENTS, LLC and ) ALEXANDRIA EQUITIES NO. 7, ) LLC, )

)

Plaintiffs, )

)

v. ) C.A. No. 2020-0593-PAF )

VERSEAU THERAPEUTICS, INC., )

)

Defendant. )

)

MEMORANDUM OPINION

Date Submitted: October 1, 2020 Date Decided: December 18, 2020

Raymond J. DiCamillo, Megan E. O’Connor, RICHARDS, LAYTON & FINGER, P.A., Wilmington, Delaware; Luke Cadigan, COOLEY LLP, Boston, Massachusetts; Patrick Gunn, COOLEY LLP, San Francisco, California; Attorneys for Plaintiffs Alexandria Venture Investments, LLC and Alexandria Equities No. 7, LLC.

David J. Teklits, Thomas P. Will, MORRIS, NICHOLS, ARSHT, & TUNNELL LLP, Wilmington, Delaware; Attorneys for Defendant Verseau Therapeutics, Inc.

FIORAVANTI, Vice Chancellor

Plaintiffs Alexandria Venture Investments, LLC (“Alexandria Venture”) and Alexandria Equities No. 7, LLC (“Alexandria Equities” and together with Alexandria Venture, “Alexandria”) seek an order to compel inspection of books and records of Verseau Therapeutics, Inc. (“Verseau” or the “Company”) pursuant to Section 220 of the Delaware General Corporation Law (“DGCL”). Alexandria aims to investigate, among other things, whether Verseau’s directors violated their fiduciary duties when they rejected a financing proposal from Alexandria. In this post-trial Opinion, I conclude that Alexandria is entitled to inspect some, but not all, of the categories of books and records sought in the demand. I. BACKGROUND The facts recited in this Opinion are the Court’s findings based on the testimony and documentary evidence presented at a half-day trial on October 1, 2020. The record includes stipulations of fact contained in the parties’ Pretrial Stipulation and Order (“PTO”), the 62 trial exhibits, and deposition testimony from one witness, Aaron Jacobson.1 The following facts were either uncontested or have been proven by a preponderance of the evidence.

1 Citations in the form “Tr.” refer to the trial transcript. Citations in the form “JX” refer to trial exhibits with pinpoint citations to the last three digits of the relevant Bates number. Citations in the form “Dep.” refer to the Jacobson deposition transcript.

A. The Parties

Verseau is a privately held Delaware corporation founded in 2017 to develop immunotherapies to treat cancer. During relevant events and at least until June 30, 2020, Verseau’s board of directors (the “Board”) consisted of seven individuals: Christine Bunt, George Golumbeski, Zhenping Zhu, Jong Chang, Wen Chen, Bob Langer, and Daniel Anderson. 2 Bunt was Verseau’s Chief Executive Officer during that same time period.3 Golumbeski is the chairman of the Board, having previously served as Executive Vice President of Business Development at Celgene Corporation (“Celgene”), a biotechnology company.4 Golumbeski initially joined Verseau as an advisor in 2018, and he continued to provide consulting services to Verseau after joining the Board in 2019.5 Golumbeski owns approximately 1% of Verseau’s stock on a fully diluted basis.6 Zhu is affiliated with 3SBio Inc. (“3SBio”), a biotechnology company based in China, where he serves as President of Research & Development and Chief Scientific Officer.7 3SBio owns 11.8% of the Company’s stock.8 Chang is the founder and chairman of InHarv Partners Ltd.

2 Pretrial Stipulation and Order (“PTO”) ¶ 7.

3 Id. ¶ 8.

4 JX 14.

5 Id.

6 Tr. 72:12–17.

7 JX 4 at ‘095–96.

8 JX 62.

(“InHarv”), a venture capital firm, 9 which owns 24.4% of the Company’s stock.10 Langer and Anderson are co-founders of Verseau.11 Plaintiffs are venture capital firms and preferred stockholders of Verseau.12 Together, Plaintiffs own 5.1% of the Company’s stock.13 Joel Marcus is the Executive Chairman of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Venture and ultimate managing member of Alexandria Equities. 14 Aaron Jacobson is Senior Vice President and Venture Counsel of Alexandria Real Estate Equities, Inc. 15 Marcus frequently attended Board meetings as one of Alexandria’s Board observers. 16 At its March 13, 2020 meeting, the Board “expressed support for adding Marcus to the Board subject to receipt of the requisite stockholder consents.” 17 The Company subsequently informed its preferred stockholders of the Board’s decision

9 Id. at ‘095.

10 JX 62. The stock ownership reported for Golumbeski, S3Bio, InHarv, and Alexandria is on a fully diluted basis. Id. 11 PTO ¶ 7.

12 PTO ¶¶ 4–5. One or more representatives of Alexandria typically attend Board meetings. See JX 51 at ‘952, ‘958; JX 40 at ‘901, ‘909. 13 JX 62.

14 PTO ¶ 9.

15 PTO ¶ 11.

16 JX 51 at ‘952, ‘958; JX 40 at ‘901, ‘909.

17 JX 40 at ‘903.

to add Marcus as a director.18 The Company told stockholders that Marcus would become a director after the stockholders agreed to expand the Board, a voting agreement was amended, and the Board formally elected Marcus.19 There is no evidence in the record that any of those events occurred, and I find that they did not.

B. Recent Hires at Verseau After Golumbeski joined the Board, Verseau hired three former Celgene employees into senior positions. In November 2019, Verseau hired Tim Smith, Celgene’s former Executive Director of Business Development, as Verseau’s new Chief Business Officer. 20 In February 2020, Verseau hired Alise Reicin, Celgene’s former President of Global Clinical Development, as Veseau’s new Chief Medical Officer.21 Verseau hired another former Celgene employee as a senior advisor that same month. 22 Smith’s time at Celgene overlapped with Golumbeski’s, 23 but there is no evidence in the record indicating that Golumbeski had directly worked with Smith.24 Reicin did not overlap with Golumbeski while at Celgene. 25

18 JX 1 at ‘093.

19 Id. at ‘093–94.

20 JX 59.

21 JX 53.

22 JX 52.

23 See JX 58, 59.

24 Dep. 22:5–23:18.

25 Id.

C. Negotiation of the Term Sheet In March 2020, Verseau needed cash, particularly to weather the global pandemic. Verseau and Alexandria, an existing Verseau stockholder, then began discussing bridge financing. On April 25, Alexandria sent to Verseau a non-binding term sheet that generally provided for Alexandria to lead a financing round of $30 million in convertible notes.26 Among other terms, the proposal provided investors a 2.0x return on investment in the event of a change in control. It also gave Alexandria the right to designate a director to serve on the Board and specified Marcus as Alexandria’s initial director designee. Bunt sent Verseau’s response a week later, stating that the proposal was generally “a fair balance for the company.”27 Verseau pushed back, however, on a few provisions, two of which are pertinent to this Opinion. 28 First, the Company resisted terms giving Alexandria significant power over Verseau’s relationship with 3SBio, where Zhu was an officer. Verseau had partnered with 3SBio on one recent project and anticipated partnering with 3SBio on a second project within the next year. 29 Alexandria’s initial proposal required approval by Alexandria’s designated Board member for any related-party

26 JX 5.

27 See JX 6.

28 Id.

29 Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc., (Del. Ct. App. 2020).

Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc. (Alexandria Venture Investments, LLC v. Verseau Therapeutics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Henshaw v. American Cement Corporation
252 A.2d 125 (Court of Chancery of Delaware, 1969)
In Re the Walt Disney Co. Derivative Litigation
825 A.2d 275 (Court of Chancery of Delaware, 2003)
CM & M GROUP, INC. v. Carroll
453 A.2d 788 (Supreme Court of Delaware, 1982)
Seinfeld v. Verizon Communications, Inc.
909 A.2d 117 (Supreme Court of Delaware, 2006)
Helnsman Management Services, Inc. v. a & S Consultants, Inc.
525 A.2d 160 (Court of Chancery of Delaware, 1987)
Kaufman v. CA, INC.
905 A.2d 749 (Court of Chancery of Delaware, 2006)
Saito v. McKesson HBOC, Inc.
806 A.2d 113 (Supreme Court of Delaware, 2002)
Security First Corp. v. U.S. Die Casting & Development Co.
687 A.2d 563 (Supreme Court of Delaware, 1997)
Thomas & Betts Corp. v. Leviton Manufacturing Co.
681 A.2d 1026 (Supreme Court of Delaware, 1996)
Pershing Square v. Ceridian Corporation
923 A.2d 810 (Court of Chancery of Delaware, 2007)
Highland Select Equity Fund, L.P. v. Motient Corp.
906 A.2d 156 (Court of Chancery of Delaware, 2006)
Delaware County Employees Retirement Fund v. Sanchez
124 A.3d 1017 (Supreme Court of Delaware, 2015)
Amalgamated Bank v. Yahoo! Inc.
132 A.3d 752 (Court of Chancery of Delaware, 2016)
KT4 Partners LLC v. Palantir Technologies, Inc.
203 A.3d 738 (Supreme Court of Delaware, 2019)